# KLOW peptide Dosing in the Research Literature > KLOW peptide dosing context: no validated human dose exists for the blend. The 80 mg vial composition, the routes studied in component research, reconstitution notes and the pharmacokinetic mismatch — research context only. No validated human dose exists for the blend. This page maps the research context, never a human-use instruction. ## Before the numbers There is no validated human dose for KLOW peptide. None. That is the whole story of this page, and the rest is just honest detail. The only fixed figure is the canonical research vial: 80 mg total, split GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg. That 80 mg is the amount of peptide in the vial — not a daily amount, and not a number anyone should read as a recommendation. Why can't the component doses simply be added up? Because the four peptides clear the body at wildly different speeds — a built-in mismatch called pharmacokinetics (how fast a compound is absorbed and cleared). BPC-157 is gone in under about half an hour in the formal study; the tiny tripeptides clear even faster [6]. A single co-formulated dose cannot keep all four at matched levels [11]. Everything below describes what was given to which species, by which route, in research — not how a person should use anything. ## Dosing in the Research Literature Component research doses span orders of magnitude and were studied in isolation, never as KLOW. BPC-157 was given to rats at 10 microg, 10 ng or 10 pg per animal in the transected-Achilles model [8], and at 400-800 ng/kg in gastric-ulcer work [21]. Thymosin beta-4 was studied in rats at 2-18 mg/kg in a stroke model (with a non-monotonic response — 18 mg/kg gave no benefit) [22] and in humans up to 1260 mg IV in a Phase 1 trial of the native protein [11]. KPV worked at nanomolar concentrations in vitro and 100 micromolar in drinking water in mice [1]. GHK-Cu acts at low-nanomolar concentrations in fibroblast cultures [2]. These numbers do not combine into a "KLOW dose" [6]. ## Dosage and frequency in research handling No validated dosage or frequency exists for the blend. The inherent pharmacokinetic mismatch is the reason: with BPC-157's elimination half-life under about 30 minutes in formal PK [6] and the tripeptides KPV and GHK-Cu clearing even faster, no single schedule keeps all four components at matched exposures [11]. Any frequency claim circulating for KLOW is a guess unsupported by blend data — the gauge for a combination dosing schedule simply reads no signal. ## Routes studied in component research There is no validated human administration for the blend, so this is research context, not a use instruction. In the component literature, routes studied include subcutaneous and intraperitoneal injection (research handling), topical application (GHK-Cu, with a measured human-skin permeability and a dermal copper depot) [13], oral and targeted delivery (KPV via PepT1-targeted nanoparticles [16]; BPC-157 in gut models [21]), and intra-articular delivery (BPC-157). Each route was studied for a single component in a specific model — none describes how the four-peptide blend should be given. ## Reconstitution and stability notes As a lyophilized (freeze-dried) research blend, KLOW is reconstituted with bacteriostatic water for laboratory handling, and the resulting solution is typically refrigerated. One chemistry note matters here: the copper(II) in GHK-Cu can take part in redox reactions, which raises a theoretical compatibility consideration when it is co-dissolved with the other three peptides in one vial [2]. This has not been formally characterized for the mixture — it is a flagged unknown, not a documented problem [5]. --- A brass-and-nebula observatory for the four-peptide KLOW record — four separate peptides charted as four orbiting bodies, what each component's studies measured surfaced first and the untested blend left as an unlit gauge, with no clinic behind the instrument and nothing here dispensed or sold.